247 related articles for article (PubMed ID: 23460320)
1. Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model.
Iwami K; Natsume A; Ohno M; Ikeda H; Mineno J; Nukaya I; Okamoto S; Fujiwara H; Yasukawa M; Shiku H; Wakabayashi T
Neuro Oncol; 2013 Jun; 15(6):747-58. PubMed ID: 23460320
[TBL] [Abstract][Full Text] [Related]
2. Diffuse midline skull base meningiomas: identification of a rare and aggressive subgroup of meningiomas.
Peyre M; Feuvret L; Sanson M; Navarro S; Boch AL; Loiseau H; Kalamarides M
J Neurooncol; 2017 Jul; 133(3):633-639. PubMed ID: 28536991
[TBL] [Abstract][Full Text] [Related]
3. New prospects for management and treatment of inoperable and recurrent skull base meningiomas.
Johnson MD; Sade B; Milano MT; Lee JH; Toms SA
J Neurooncol; 2008 Jan; 86(1):109-22. PubMed ID: 17624496
[TBL] [Abstract][Full Text] [Related]
4. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
[TBL] [Abstract][Full Text] [Related]
5. mTORC1 inhibitors suppress meningioma growth in mouse models.
Pachow D; Andrae N; Kliese N; Angenstein F; Stork O; Wilisch-Neumann A; Kirches E; Mawrin C
Clin Cancer Res; 2013 Mar; 19(5):1180-9. PubMed ID: 23406776
[TBL] [Abstract][Full Text] [Related]
6. Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety.
Ochi T; Fujiwara H; Okamoto S; An J; Nagai K; Shirakata T; Mineno J; Kuzushima K; Shiku H; Yasukawa M
Blood; 2011 Aug; 118(6):1495-503. PubMed ID: 21673345
[TBL] [Abstract][Full Text] [Related]
7. Clear cell meningiomas: three case reports with genetic characterization and review of the literature.
Ohba S; Sasaki H; Kimura T; Ikeda E; Kawase T
Neurosurgery; 2010 Sep; 67(3):E870-1; discussion E871. PubMed ID: 20683214
[TBL] [Abstract][Full Text] [Related]
8. The Wilms' tumor suppressor WT1 enhances CD95L expression and promotes activation-induced cell death in leukemic T cells.
Bourkoula K; Englert C; Giaisi M; Köhler R; Krammer PH; Li-Weber M
Int J Cancer; 2014 Jan; 134(2):291-300. PubMed ID: 23832418
[TBL] [Abstract][Full Text] [Related]
9. WT1 promotes invasion of NSCLC via suppression of CDH1.
Wu C; Zhu W; Qian J; He S; Wu C; Chen Y; Shu Y
J Thorac Oncol; 2013 Sep; 8(9):1163-9. PubMed ID: 23945386
[TBL] [Abstract][Full Text] [Related]
10. Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.
Takahara A; Koido S; Ito M; Nagasaki E; Sagawa Y; Iwamoto T; Komita H; Ochi T; Fujiwara H; Yasukawa M; Mineno J; Shiku H; Nishida S; Sugiyama H; Tajiri H; Homma S
Cancer Immunol Immunother; 2011 Sep; 60(9):1289-97. PubMed ID: 21607557
[TBL] [Abstract][Full Text] [Related]
11. TGF-beta1 reduces Wilms' tumor suppressor gene expression in podocytes.
Sakairi T; Abe Y; Kopp JB
Nephrol Dial Transplant; 2011 Sep; 26(9):2746-52. PubMed ID: 21378152
[TBL] [Abstract][Full Text] [Related]
12. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
13. Molecular genetics of meningiomas: a systematic review of the current literature and potential basis for future treatment paradigms.
Pham MH; Zada G; Mosich GM; Chen TC; Giannotta SL; Wang K; Mack WJ
Neurosurg Focus; 2011 May; 30(5):E7. PubMed ID: 21529178
[TBL] [Abstract][Full Text] [Related]
14. Correlation of Wilms' tumor 1 isoforms with HER2 and ER-α and its oncogenic role in breast cancer.
Nasomyon T; Samphao S; Sangkhathat S; Mahattanobon S; Graidist P
Anticancer Res; 2014 Mar; 34(3):1333-42. PubMed ID: 24596380
[TBL] [Abstract][Full Text] [Related]
15. A narrative review of targeted therapy in meningioma, pituitary adenoma, and craniopharyngioma of the skull base.
Martinez NL; Khanna O; Farrell CJ
Chin Clin Oncol; 2020 Dec; 9(6):75. PubMed ID: 32819111
[TBL] [Abstract][Full Text] [Related]
16. Landscape of immune cell gene expression is unique in predominantly WHO grade 1 skull base meningiomas when compared to convexity.
Zador Z; Landry AP; Balas M; Cusimano MD
Sci Rep; 2020 Jun; 10(1):9065. PubMed ID: 32493984
[TBL] [Abstract][Full Text] [Related]
17. Preoperative Embolization of Skull Base Meningiomas: Outcomes in the Onyx Era.
Przybylowski CJ; Baranoski JF; See AP; Flores BC; Almefty RO; Ding D; Chapple KM; Sanai N; Ducruet AF; Albuquerque FC
World Neurosurg; 2018 Aug; 116():e371-e379. PubMed ID: 29751190
[TBL] [Abstract][Full Text] [Related]
18. Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice.
Xue SA; Gao L; Thomas S; Hart DP; Xue JZ; Gillmore R; Voss RH; Morris E; Stauss HJ
Haematologica; 2010 Jan; 95(1):126-34. PubMed ID: 19679884
[TBL] [Abstract][Full Text] [Related]
19. WT1 regulates angiogenesis in Ewing Sarcoma.
Katuri V; Gerber S; Qiu X; McCarty G; Goldstein SD; Hammers H; Montgomery E; Chen AR; Loeb DM
Oncotarget; 2014 May; 5(9):2436-49. PubMed ID: 24810959
[TBL] [Abstract][Full Text] [Related]
20. An orthotopic skull base model of malignant meningioma.
Baia GS; Dinca EB; Ozawa T; Kimura ET; McDermott MW; James CD; VandenBerg SR; Lal A
Brain Pathol; 2008 Apr; 18(2):172-9. PubMed ID: 18093250
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
